Alto Neuroscience bags $25M for four Phase II drugs (Endpoints News):
Another $25 million is flowing the way of a California biotech attempting to fix the “trial and error” system in neuroscience drug R&D.
Alto Neuroscience picked up the capital from Alpha Wave Ventures via an extension to its Series B, bringing total equity raised to $100 million since the startup’s 2019 founding. [Read more…] about Alto Neuroscience raises $60M (equity + credit) to help fix the “trial and error” approach to psychiatric medication